You are viewing: China AI in Life Science Market analysis
Part of: AI in Life Science Market (Global)

The China AI in Life Science Market was valued at $1674.3 Million in 2026 and projected to reach to $5485.8 Million by 2031, representing a compound annual growth rate of 26.8%. China's AI in Life Science market is positioned for exceptional growth through 2031, driven by government initiatives, substantial R&D investments, and the nation's digital health transformation agenda.

China AI in Life Science Market (2026-2031) : Size and Share
logo-mobile
CAGR of
cagr-Chart
USD Million
MARKET SNAPSHOT
Market Size in USD 26.32 MN
Market Forecast in
CAGR
Forecast Period
Units Considered Value (USD MN)

China AI in Life Science Market Trends and Insights

  • This represents a compound annual growth rate of 26.8%, driven by China's substantial investments in healthcare innovation and artificial intelligence infrastructure.
  • China's government support for digital health initiatives and the country's large patient population create significant opportunities for AI-powered diagnostic and therapeutic solutions. The market growth in China reflects the nation's strategic focus on becoming a global leader in AI and biotechnology.
  • China's pharmaceutical and healthcare sectors are increasingly adopting machine learning algorithms for drug discovery, clinical trial optimization, and personalized medicine.
  • By 2031, China is expected to capture a substantial share of the Asia Pacific AI in Life Science market, positioning the country as a critical hub for innovation in this sector. China's competitive advantages include a robust tech ecosystem, abundant data resources, and a growing pool of AI talent.
  • The integration of AI into China's healthcare system is accelerating clinical outcomes while reducing operational costs, making China an attractive market for both domestic and international life science companies..

Key Market Statistics

  • CAGR (2026-2031) 26.8% CAGR
  • Market Size, 2026 ~USD 1674.3 Million
  • Forecast, 2031 ~USD 5485.8 Million
  • Country China

China AI in Life Science Market Overview

Rapid Market Expansion :

China's AI in Life Science market is projected to grow from $1,674.3 million in 2026 to $5,485.8 million by 2031, representing a robust 26.8% CAGR, outpacing the global average of 26.3%.

Government-Backed Innovation :

China's government actively supports digital health initiatives and AI infrastructure development, creating a favorable regulatory environment and substantial funding opportunities for life science AI applications.

Large Patient Population Advantage :

With over 1.4 billion residents, China's vast population provides extensive datasets and real-world evidence opportunities for training and validating AI algorithms in clinical settings.

Strategic Healthcare Modernization :

China's commitment to healthcare innovation and digital transformation is driving adoption of AI-powered diagnostics, drug discovery, and personalized medicine solutions across hospitals and research institutions.

China AI in Life Science Market Dynamics

  • The country's competitive advantage lies in its massive patient population, advanced computing infrastructure, and supportive regulatory framework that accelerates AI deployment in clinical and research environments. Key growth catalysts include increasing adoption of AI-powered diagnostic tools, drug discovery acceleration, and personalized medicine platforms.
  • Chinese biotech companies and healthcare providers are rapidly integrating machine learning solutions, while international partnerships are expanding market opportunities.
  • This trajectory positions China as a global leader in AI-driven life science innovation..

Related Ecosystem

Healthcare It

Top Technologies
  • Computed Tomography (CT)
  • Machine Learning
  • Magnetic Resonance Imaging (MRI)
  • Natural Language Processing (NLP)
  • Predictive Analytics
Top Companies
  • CERNER CORPORATION
  • PHILIPS HEALTHCARE
  • Oracle Corporation
  • GE HealthCare Technologies Inc.
  • Siemens healthineers

    Key Takeaways

    • China's AI in Life Science market will grow from $1,674.3M (2026) to $5,485.8M (2031) at a 26.8% CAGR.
    • China's government backing and digital health initiatives are primary catalysts for market expansion.
    • China's large patient population and data availability create unique advantages for AI-driven healthcare solutions.
    • China is positioned to become a dominant player in Asia Pacific's AI in Life Science sector by 2031.

    AI in Life Science Market Report Scope

    Report Metric Details
    Base Year 2026
    Fastest Growing Segment NATURAL LANGUAGE PROCESSING (Tool)
    Forecast Period 2026–2031
    Growth Rate CAGR of 26.3% from 2026 to 2031
    Largest Segment CLINICAL APPLICATIONS (Application)
    Market Size Base Year (Billions) ~USD 21.58 (2026)
    Revenue Forecast (Billions) ~USD 69.34 (2031)
    Segments Covered Tool, Type, Application, Component, Deployment, End User, Offering, Deployment Mode

    China AI in Life Science Market Report Segmentation

    8 segment dimensions are covered across the global market.

    By Tool

    • Computer Vision
    • Context-Aware Processing And Computing
    • Image Analysis (Including Optical Character Recognition)
    • Machine Learning
    • Natural Language Processing

    By Type

    • Clinical Trials
    • Convolutional Neural Networks
    • Data Analytics & Reporting
    • Deep Learning
    • Drug Discovery
    • Generative Adversarial Networks
    • Graph Neural Networks
    • Manufacturing & Quality Assurance
    • Medical Imaging & Diagnostics
    • Other Clinical Applications
    • Other Machine Learning Technologies
    • Precision Medicine
    • R&D Support
    • Recurrent Neural Networks
    • Regulatory Affairs
    • Reinforcement Learning
    • Supervised Learning
    • Unsupervised Learning

    By Application

    • Clinical Applications
    • Non-Clinical Applications

    By Component

    • Service
    • Services
    • Software

    By Deployment

    • Cloud-Based Solutions
    • Hybrid Solutions
    • On-Premise Solutions

    By End User

    • Academic & Government Laboratories
    • Biotechnology Companies
    • Cro & Cdmo
    • Diagnostic Companies
    • Other End Users
    • Pharmaceutical Companies

    By Offering

    • AI Technology
    • End-To-End Solutions
    • Niche/Point Solutions
    • Services

    By Deployment Mode

    • Cloud-Based Solutions
    • Hybrid Solutions
    • On-Premise Solutions

    CHINA: AI IN LIFE SCIENCE MARKET, BY END USER, 2024–2031

    Segment20242025202620272028202920302031CAGR (%)
    ACADEMIC & GOVERNMENT LABORATORIES56.670.389113.4142.7181.3229285.826.3
    BIOTECHNOLOGY COMPANIES262.9328.5418.8536.8680.2869.91105.61389.427.1
    CRO & CDMO172.8214.8272.3347.1437.4556.3703.2878.726.4
    DIAGNOSTIC COMPANIES125155.9198.3253.7320.8409.5519.5651.526.9
    OTHER END USERS28.935.444.355.769.186.6107.7132.424.5
    PHARMACEUTICAL COMPANIES410.1511.8651.6834.21055.61348.41711.5214826.9
    TOTAL1056.41316.71674.32140.92705.83452.14376.55485.826.8

    Target Audience

    • Healthcare Technology Investors : Investors seeking high-growth opportunities in China's AI life science sector need detailed market sizing, growth projections, and opportunity analysis to allocate capital effectively in this 26.8% CAGR market.
    • Pharmaceutical & Biotech Companies : Pharma and biotech firms expanding into China require market intelligence on AI adoption rates, competitive landscape, regulatory requirements, and partnership opportunities for drug discovery and development.
    • Healthcare IT & AI Solution Providers : Software and AI vendors targeting China's healthcare sector need market data, customer segments, adoption trends, and competitive positioning to develop localized solutions and go-to-market strategies.
    • Hospital Networks & Healthcare Providers : Chinese healthcare institutions and hospital networks need insights on AI implementation trends, vendor landscape, and ROI benchmarks to make informed technology investment and procurement decisions.
    • Government & Policy Makers : Chinese government agencies and health policy officials require market analysis to inform digital health strategy, funding allocation, and regulatory frameworks supporting AI innovation in life sciences.

    Key Companies in the China AI in Life Science Market

    CompanyHQOwnershipStrongest segments
    NVIDIA CORPORATIONUnited StatesPublic CompanyData Center AI & Accelerated Computing (Compute & Networking),Gaming GPUs (GeForce),Professional Visualization (RTX/Quadro),
    ILLUMINA, INC.United StatesPublic CompanySequencing instruments,Sequencing consumables (reagents, flow cells, library prep, WGS and targeted kits),Array-based instruments and consumables,
    TEMPUS AI, INC.United StatesPublic CompanyOncology NGS diagnostics (xT, xR, large-panel solid and hematologic assays),Other clinical diagnostics (PCR, pathology, germline, pharmacogenomics nP),Life sciences data, AI platforms, and software (Lens, Insights, Next, Algos, Organoids, Trials),
    RECURSIONUnited StatesPublic CompanyPlatform and collaboration revenue,Internal pipeline and other revenue,
    DASSAULT SYSTèMES SEFrancePublic Company3D Modeling (CATIA, SOLIDWORKS, GEOVIA, BIOVIA),PLM & Collaboration (ENOVIA, CENTRIC PLM, 3DEXCITE, 3DEXPERIENCE collaboration),Simulation & Manufacturing (SIMULIA, DELMIA, 3DVIA),
    SCHRÖDINGER, INC.United StatesPublic CompanySoftware,Drug Discovery – Collaborations and Milestones,Drug Discovery – Internal Programs and Other,
    MICROSOFT CORPORATIONUnited StatesPublic CompanyProductivity and Business Processes,Intelligent Cloud,Personal Computing,
    BENEVOLENTAI LIMITEDUnited KingdomPrivate CompanyAI R&D decision-support platform (licenses and subscriptions),Collaborative discovery projects and services,Data and ontology integration / customization,

    NVIDIA CORPORATION

    NVIDIA Corporation is a U.S. public company founded in 1993 that employs 42,000 people. The company designs and manufactures graphics processing units and system-on-chip units for gaming, professional visualization, data centers, and artificial intelligence applications.

    ILLUMINA, INC.

    Illumina, Inc. is a U.S. public company founded in 1998 with 8,625 employees. The company develops and manufactures sequencing and array-based solutions for genetic analysis and molecular diagnostics.

    TEMPUS AI, INC.

    Tempus AI, Inc. is a U.S. public company founded in 2015 with 3,800 employees. The company applies artificial intelligence and machine learning to healthcare data to improve clinical decision-making and patient outcomes.

    RECURSION

    Recursion is a U.S. public company founded in 2013 with 600 employees. The company uses artificial intelligence and high-throughput biology to discover and develop novel therapeutics.

    DASSAULT SYSTèMES SE

    Dassault Systèmes SE is a French public company founded in 1981 with 25,000 employees. The company develops and markets 3D design, digital mock-up, and product lifecycle management software solutions.

    SCHRÖDINGER, INC.

    Schrödinger, Inc. is a U.S. public company founded in 1990 with 850 employees. The company provides computational chemistry and molecular simulation software platforms for drug discovery and materials science.

    MICROSOFT CORPORATION

    Microsoft Corporation is a U.S. public company founded in 1975 with 228,000 employees. The company develops, manufactures, and sells computer software, consumer electronics, personal computers, and cloud computing services.

    BENEVOLENTAI LIMITED

    BenevolentAI Limited is a United Kingdom private company founded in 2013 with 173 employees. The company uses artificial intelligence to accelerate drug discovery and development for various therapeutic areas.

    Reasons to Buy this Report

    • Market Size & Growth Validation : Obtain precise market valuation data for China ($1,674.3M in 2026, $5,485.8M in 2031) with verified 26.8% CAGR to support investment decisions and competitive positioning strategies.
    • China-Specific Opportunity Mapping : Identify high-potential segments within China's AI life science ecosystem, including diagnostic AI, drug discovery platforms, and personalized medicine applications tailored to the Chinese market.
    • Government Policy & Regulatory Insights : Understand China's digital health initiatives, government support mechanisms, and regulatory landscape to navigate market entry, partnerships, and compliance requirements effectively.
    • Competitive Intelligence for China : Benchmark against local and international competitors operating in China's market, identify market gaps, and develop targeted strategies for market penetration and expansion.
    • Investment & Partnership Strategy : Leverage detailed China market data to identify investment opportunities, potential acquisition targets, and strategic partnership prospects in the rapidly growing AI life science sector.

    Frequently asked questions

    What is the current size of China's AI in Life Science market?

    China's AI in Life Science market is valued at $1,674.3 million in 2026 and is expected to grow to $5,485.8 million by 2031.

    What is the growth rate of China's AI in Life Science market?

    China's AI in Life Science market is growing at a compound annual growth rate (CAGR) of 26.8% from 2026 to 2031.

    What factors are driving growth in China's AI in Life Science market?

    Key drivers include government support for digital health, substantial investments in AI infrastructure, a large patient population, and the adoption of machine learning in drug discovery and clinical trials.

    How does China's market compare to the global AI in Life Science market?

    China's 26.8% CAGR slightly exceeds the global CAGR of 26.3%, indicating that China is growing faster than the global average and gaining market share.

    What applications of AI are most prevalent in China's life science sector?

    China's life science sector is leveraging AI for drug discovery, clinical trial optimization, personalized medicine, diagnostic imaging, and healthcare system efficiency improvements.

    RESEARCH METHODOLOGY

    The study involved five major activities to estimate the current size of the AI in life science market. Exhaustive secondary research was conducted to collect information on the market and its subsegments. The next step was to validate these findings, assumptions, and sizing with industry experts across the value chain through primary research. Both top-down and bottom-up approaches were employed to estimate the total market size. Thereafter, market breakdown and data triangulation procedures were used to estimate the market size of the segments and subsegments.  

    Secondary Research

    In the secondary research process, various secondary sources, including annual reports, press releases and investor presentations from companies, white papers, certified publications, articles by recognized authors, gold- and silver-standard websites, regulatory bodies, and databases (such as D&B Hoovers, Bloomberg Business, and Factiva), were consulted to identify and collect information for the study of the AI in the life science market. These sources were also used to obtain important information about the top players, market classification and segmentation by industry trends down to the bottom-most level, geographic markets, and key developments related to the market. A database of key industry leaders was also prepared using secondary research.

    Primary Research

    Extensive primary research was conducted after obtaining basic information of the global AI in life science market through secondary research. Several primary interviews were conducted with market experts from both the demand side (hospital directors, hospital vice presidents, department heads, and critical care specialists) and the supply side (such as C- and D-level executives, technology experts, product managers, marketing and sales managers, among others) across five major regions, including North America, Europe, the Asia-Pacific, Latin America, the Middle East, and Africa. This primary data was collected through questionnaires, emails, online surveys, personal interviews, and telephone interviews.

    The following is a breakdown of the primary respondents:

    BREAKDOWN OF PRIMARY PARTICIPANTS:

    AI in Life Science Market Size, and Share

    Note 1: Others include sales managers, marketing managers, and product managers.
    Note 2: Tiers of companies are defined on the basis of their total revenues in 2025. Tier 1 = >USD 1 billion, Tier 2 = USD 500 million to USD 1 billion, and Tier 3 = <USD 500 million.

    To know about the assumptions considered for the study, download the pdf brochure

    Market Size Estimation

    Both top-down and bottom-up approaches were used to estimate and validate the total size of the AI in life science market. These methods were also used extensively to estimate the size of various subsegments in the market.

    AI in Life Science Market : Top-Down and Bottom-Up Approach

    AI in Life Science Market Top Down and Bottom Up Approach

    Data Triangulation

    After determining the overall market size using market size estimation processes, the market was segmented into several segments and subsegments. To complete the overall market engineering process and arrive at the exact statistics for each market segment and subsegment, data triangulation and market breakdown procedures were employed wherever applicable. The data was triangulated by analyzing various factors and trends from both the demand and supply sides in the AI in life science market. 

    Market Definition

    AI in life sciences refers to the application of artificial intelligence technologies to analyze complex biological, clinical, and healthcare data to improve research, development, and patient outcomes. It uses advanced algorithms and computational models to support areas such as drug discovery, disease diagnosis, clinical trials, and precision medicine, enabling faster insights and more efficient decision-making across the life sciences ecosystem.

    Key Stakeholders

    • Pharmaceutical & Biotechnology Companies
    • Contract Research Organizations (CROs) & Clinical Trial Partners
    • Healthcare Providers (Hospitals, Clinics, Telehealth Providers)
    • Digital Health & AI Solution Providers
    • Cloud & Data Infrastructure Providers
    • Data Analytics & Software Platform Providers
    • Payers & Insurance Companies
    • Regulatory & Compliance Bodies (e.g., FDA, EMA)
    • Academic & Research Institutions
    • Patients & End Users
    • Technology Integrators & Consulting Firms

    Report Objectives

    • To define, describe, and forecast the global AI in life science market based on type, therapeutic area, application, end user, and region
    • To provide detailed information regarding the major factors (such as drivers, restraints, opportunities, and challenges) influencing market growth
    • To strategically analyze micro-markets with respect to individual growth trends, prospects, and contributions to the overall AI in life science market
    • To analyze opportunities in the market for stakeholders and provide details of the competitive landscape for market leaders
    • To strategically analyze the market structure profile of the key players of the AI in life science market and comprehensively analyze their core competencies
    • To forecast the size of the market segments with respect to five regions: North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa
    • To analyze competitive developments such as product launches and enhancements, investments, partnerships, collaborations, acquisitions, expansions, product approval, and alliances in the AI in life science market during the forecast period

    Available customizations:

    With the given market data, MarketsandMarkets offers customizations as per the company’s specific needs. The following customization options are available for the report:

    Product Analysis

    • Product matrix, which gives a detailed comparison of the product portfolios of each company.

    Regional Analysis

    • Further breakdown of the Latin America, Europe, and Middle East & Africa AI in life science market into specific countries

    Get the Full AI in Life Science Market Report

    Full forecast, segment splits, and company analysis for all AI in Life Science Market.

    Need a Tailored Report?

    Customize this report to your needs

    Get 10% FREE Customization

    Customize This Report
    Fact checked
    DMCA.com Protection Status